Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
This article was originally published in The Pink Sheet Daily
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
You may also be interested in...
Colorectal cancer label sought next, company tells “The Pink Sheet” DAILY.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.